Public Release: 

Signatures of kidney transplant rejection and acceptance

JCI Journals

Three new reports describe biomarkers that identify either kidney transplant recipients likely to maintain excellent and stable allograft function in the absence of immunosuppressive drugs or those at risk of losing their transplants. Peter Heeger and Bernd Schröppel, at Mount Sinai School of Medicine, New York, describe in an accompanying commentary, the importance of these studies and how they might impact the management of patients in the clinic to provide a more personalized treatment regimen.

The most common solid organ transplant procedure performed in the US is kidney transplantation for the treatment of end-stage kidney disease. Transplant recipients must take immunosuppressive drugs for the rest of their lives to prevent rejection of their transplanted kidney, and this has serious negative health consequences. Furthermore, these drugs do not prevent either late-stage rejection of the transplant or transplant failure. To improve long-term outcomes it would be helpful if physicians could determine whether a patient was at risk of losing their transplanted kidney or whether a patient's immune system was sufficiently tolerant of the transplanted kidney that they could stop taking their immunosuppressive drugs.

Two teams of researchers -- one led by Maria Hernandez-Fuentes, at King's College London, United Kingdom, and the other led by Kenneth Newell, at Emory University, Atlanta, Laurence Turka, at Beth Israel Deaconess Medical Center, Boston, and Vicki Seyfert-Margolis, at Immune Tolerance Network, Bethesda, -- independently identified and studied rare kidney transplant recipients who have excellent and stable graft function despite no longer taking their immunosuppressive drugs. Both groups identified a signature that was associated with this outcome and both signatures were indicative of immune cells known as B cells having a beneficial role. In contrast, in the third study, researchers led by Philip Halloran, at the University of Alberta, Edmonton, identified in patients who had received their kidney transplant more than a year prior to the analysis a molecular signature indicative of future organ failure. All three groups hope that if validated in further studies their signatures might help physicians design more personalized treatment regimens for kidney transplant recipients, for example identifying those that might be candidates for drug-weaning protocols.

###

TITLE: Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans

AUTHOR CONTACT:
Maria Hernandez-Fuentes
King's College London, Guy's Hospital, London, United Kingdom.
Phone: 44.20718.85435; Fax: 44.20718.83638; E-mail: maria.hernandez@kcl.ac.uk.

View this article at: http://www.jci.org/articles/view/39922?key=49040753bf93809451f5

ACCOMPANYING ARTICLE
TITLE: Identification of a B cell signature associated with renal transplant tolerance in humans

AUTHOR CONTACT:
Kenneth A. Newell
Emory University, Atlanta, Georgia, USA.
Phone: 404.727.2489; Fax: 404.727.3660; E-mail: kanewell@emory.edu.

Laurence A. Turka
Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Phone: 617.735.2919; Fax: 617.735.2902; E-mail: lturka@bidmc.harvard.edu.

Vicki L. Seyfert-Margolis
Food and Drug Administration, Silver Spring, Maryland, USA.
Phone: 301.796.5307; Fax: 301.847.3533; E-mail: Vicki.Seyfert-Margolis@fda.hhs.gov.

View this article at: http://www.jci.org/articles/view/39933?key=d2c548238630efc1daa6

ACCOMPANYING ARTICLE
TITLE: A molecular classifier for predicting future graft loss in late kidney transplant biopsies

AUTHOR CONTACT:
Philip F. Halloran
Alberta Transplant Applied Genomics Centre, University of Alberta, Edmonton, Alberta, Canada.
Phone: 780.407.8880; Fax: 780.407.3417; E-mail: phil.halloran@ualberta.ca.

View this article at: http://www.jci.org/articles/view/41789?key=7c600d8645775c4229a2

ACCOMPANYING COMMENTARY
TITLE: Gazing into a crystal ball to predict kidney transplant outcome

AUTHOR CONTACT:
Peter S. Heeger
Mount Sinai School of Medicine, New York, New York, USA.
Phone: 212.241.6324; Fax: 212.987.0389; E-mail: peter.heeger@mssm.edu

View this article at: http://www.jci.org/articles/view/43286?key=d11a51ae2927a3000427

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.